Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as an important nosocomial pathogen in recent decades, being responsible for an increasing proportion of patients with Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP). On the other hand, many areas in the world have experienced an alarming emergence of infections and particularly pneumonias caused by the so-called Community-Acquired MRSA (CA-MRSA), a genetically distinct strain, which shares common clinical and microbiological features with nosocomial MRSA. This paper reviews the latest epidemiological and therapeutic data and discusses currently available and future treatment options. A recent significant epidemiological feature is the “creep” observed in vancomycin minimal inhibitory concentrations. As new clinical and PK data are available relating to the use of vancomycin and linezolid, which have both been first-line options in the treatment of MRSA pneumonia in the last decade, recently issued guidelines and arguments for their revision are discussed.
Keywords: Antimicrobials, CA-MRSA, linezolid, MRSA, pneumonia, vancomycin, pathogen, Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia, mecA gene
Current Respiratory Medicine Reviews
Title:Pneumonia Due to Methicilin-Resistant Staphylococcus aureus (MRSA): A Review
Volume: 8 Issue: 3
Author(s): Garyphallia Poulakou, Jessica Souto, Nina Kmet Lunacek and Jordi Rello
Affiliation:
Keywords: Antimicrobials, CA-MRSA, linezolid, MRSA, pneumonia, vancomycin, pathogen, Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia, mecA gene
Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as an important nosocomial pathogen in recent decades, being responsible for an increasing proportion of patients with Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP). On the other hand, many areas in the world have experienced an alarming emergence of infections and particularly pneumonias caused by the so-called Community-Acquired MRSA (CA-MRSA), a genetically distinct strain, which shares common clinical and microbiological features with nosocomial MRSA. This paper reviews the latest epidemiological and therapeutic data and discusses currently available and future treatment options. A recent significant epidemiological feature is the “creep” observed in vancomycin minimal inhibitory concentrations. As new clinical and PK data are available relating to the use of vancomycin and linezolid, which have both been first-line options in the treatment of MRSA pneumonia in the last decade, recently issued guidelines and arguments for their revision are discussed.
Export Options
About this article
Cite this article as:
Poulakou Garyphallia, Souto Jessica, Kmet Lunacek Nina and Rello Jordi, Pneumonia Due to Methicilin-Resistant Staphylococcus aureus (MRSA): A Review, Current Respiratory Medicine Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339812800493250
DOI https://dx.doi.org/10.2174/157339812800493250 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Phages for the Removal of Infectious Biofilms
Current Pharmaceutical Biotechnology Design and Synthesis of Novel Anti-inflammatory/Anti-ulcer Hybrid Molecules with Antioxidant Activity
Medicinal Chemistry Treatment Options for Persistent Coagulase Negative Staphylococcal Bacteremia in Neonates
Current Pediatric Reviews Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science <i>Propionibacterium acnes</i> in the Pathogenesis and Immunotherapy of Acne Vulgaris
Current Drug Metabolism Thoracic Aortic Aneurysm: Blood Pressure and Inflammation as Key Factors in the Development of Aneurysm Dissection
Current Pharmaceutical Design Adenotonsillar Disease
Recent Patents on Inflammation & Allergy Drug Discovery Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus
Current Pharmaceutical Biotechnology Prevalence and Resistance Profiles of Vancomycin-resistant Enterococcal Isolates in Iran; An Eight-month Report from Nine Major Cities
Infectious Disorders - Drug Targets The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials Antibiotic Prophylaxis in Urologic Prosthetic Surgery
Current Pharmaceutical Design Editorial: “Ah, Wherefore with Infection Should he Live?”: Microbial Virulence Factors in Diabetic Foot Ulceration
Current Vascular Pharmacology Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews The Role of the Coagulase-negative Staphylococci (CoNS) in Infective Endocarditis; A Narrative Review from 2000 to 2020
Current Pharmaceutical Biotechnology Infective Endocarditis Complicating Hypertrophic Obstructive Cardiomyopathy: Is Antibiotic Prophylaxis Really Unnecessary?
Current Cardiology Reviews New Approaches to Develop Anti-Staphylococcal Agents
Current Medicinal Chemistry - Anti-Infective Agents Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Heart Failure in South America
Current Cardiology Reviews Best Practice for Atrial Fibrillation Patient Education
Current Pharmaceutical Design Endophthalmitis
Anti-Infective Agents in Medicinal Chemistry